Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05564026 · ClinicalTrials.gov registry record
Molecular Epidemiology of Pediatric Germ Cell Tumors
A clinical trial of Germ Cell Tumor and Yolk Sac Tumor, sponsored by Children's Oncology Group.
- Recruiting
- Registry status
- 1,151
- Enrollment target
- 1
- Study location
NCT05564026: Recruiting study of Germ Cell Tumor and Yolk Sac Tumor, sponsored by Children's Oncology Group.
NCT05564026 is a study of Germ Cell Tumor and Yolk Sac Tumor that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 1,151 participants, above the 287-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (301% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05564026, a study of Germ Cell Tumor and Yolk Sac Tumor, is actively recruiting participants, sponsored by Children's Oncology Group.
- RECRUITING
- Registry status
- 1,151 participants
- Enrollment target
- 1
- Study location
Study Summary
A Non-Therapeutic Study that aims to establish a cohort of GCT survivors to understand short term and long-term adverse effects of treatment and to conduct molecular analyses to improve risk stratification.
Primary Outcome
Ototoxicity as determined by central review of end of therapy audiograms will serve as the primary outcome variable for analyses. Current ototoxicity will be assessed using an app-based hearing assessment. For the app-based audiometry assessment, unilateral hearing loss will be defined as at least one pure tone threshold greater than 25 decibels across at any one of the frequencies from 2,000 Hz- 8,000 Hz to align with the SIOP Boston guidelines, while bilateral hearing loss will be defined as a
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- PROCEDURE Blood Sample Collection
- OTHER Tumor Specimen Collection
- OTHER Germline DNA Samples
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,151 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2027-06-30 |
What NCT05564026 shows while recruiting
NCT05564026 is an observational study that tracks outcomes without assigning an intervention. Its 1,151 participants enrollment target places it among the larger protocols in the corpus, above the 287-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (301% higher).
The record links to 9 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT05564026 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05564026 about?
NCT05564026 is a clinical study titled "Molecular Epidemiology of Pediatric Germ Cell Tumors". A Non-Therapeutic Study that aims to establish a cohort of GCT survivors to understand short term and long-term adverse effects of treatment and to conduct molecular analyses to improve risk stratification.
What is the current status of trial NCT05564026?
This trial is currently recruiting. The enrollment target is 1,151 participants. The study started on 2023-04-12. Estimated completion is 2027-06-30.
What conditions does trial NCT05564026 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Yolk Sac Tumor, Choriocarcinoma, Mixed Germ Cell Tumor, Teratoma.
What interventions are being tested in trial NCT05564026?
The interventions under investigation include: Questionnaire Administration (OTHER), Blood Sample Collection (PROCEDURE), Tumor Specimen Collection (OTHER), Germline DNA Samples (OTHER).
Who is sponsoring clinical trial NCT05564026?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05564026 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05564026's enrollment target sits among peer trials
1,151 2nd of 19 the highest of 19 other Germ Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Germ Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
RECRUITING · Phase 3
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
Germ Cell Tumor and Testicular Tumor DNA Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04474301 · 1,152 participants
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- NCT07293559 · 1,150 participants
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI